{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:52:23Z","timestamp":1772214743879,"version":"3.50.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019820","name":"Promega","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The fast rate of viral mutations of SARS CoV-2 result in decrease in the efficacy of the vaccines that have been developed before the emergence of these mutations. Thus, it is believed that using additional measures to combat the virus is not only advisable but also beneficial. Two antiviral drugs were authorized for emergency use by the FDA, namely Pfizer\u2019s two-drug regimen sold under the brand name Paxlovid, and Merck\u2019s drug Lagevrio. Pfizer\u2019s two-drug combination consists of nirmatrelvir, a protease inhibitor that blocks coronavirus ability to multiply and another antiviral, ritonavir, that lowers the rate of drug clearance to boost the longevity and activity of the protease inhibitor. Merck\u2019s drug Lagevrio (molnupiravir) is a nucleoside analogue with a mechanism of action that aims to introduce errors into the genetic code of the virus. We believe the armament against the virus can be augmented by the addition of another class of enzyme inhibitors that are required for viral survival and its ability to replicate. Enzymes like nsp14 and nsp10\/16 methyltransferases (MTases) represent another class of drug targets since they are required for viral RNA translation and evading the host immune system. In this communication, we have successfully verified that the MTase-Glo, which is universal and homogeneous MTase assay can be used to screen for inhibitors of the two pivotal enzymes nsp14 and nsp16 of SARS CoV-2. Furthermore, we have carried out extensive studies on those enzymes using different RNA substrates and tested their activity using various inhibitors and verified the utility of this assay for use in drug screening programs. We anticipate our work will be pursued further to screen for large libraries to discover new and selective inhibitors for the viral enzymes particularly that these enzymes are structurally different from their mammalian counterparts.<\/jats:p>","DOI":"10.1371\/journal.pone.0274343","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T13:59:31Z","timestamp":1669730371000},"page":"e0274343","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["High throughput bioluminescent assay to characterize and monitor the activity of SARS-CoV-2 methyltransferases"],"prefix":"10.1371","volume":"17","author":[{"given":"Kevin","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hicham","family":"Zegzouti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-226X","authenticated-orcid":true,"given":"Said","family":"Goueli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"13","key":"pone.0274343.ref001","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1042\/BCJ20210219","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase","volume":"478","author":"S Basu","year":"2021","journal-title":"Biochemical Journal"},{"issue":"6","key":"pone.0274343.ref002","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1042\/BST20200396","article-title":"A pocket guide on how to structure SARS-CoV-2 drugs and therapies","volume":"48","author":"DR Littler","year":"2020","journal-title":"Biochemical Society Transactions"},{"issue":"2","key":"pone.0274343.ref003","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/nar\/gkab1279","article-title":"Coronaviral RNA-methyltransferases: function, structure and inhibition","volume":"50","author":"R Nencka","year":"2022","journal-title":"Nucleic Acids Research"},{"issue":"5","key":"pone.0274343.ref004","doi-asserted-by":"crossref","first-page":"e1008536","DOI":"10.1371\/journal.ppat.1008536","article-title":"The hallmarks of COVID-19 disease","volume":"16","author":"D Tang","year":"2020","journal-title":"PLOS Pathogens"},{"issue":"6","key":"pone.0274343.ref005","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2020.12.039","article-title":"Messenger RNA vaccines against SARS-CoV-2","volume":"184","author":"EJ Topol","year":"2021","journal-title":"Cell"},{"issue":"616","key":"pone.0274343.ref006","doi-asserted-by":"crossref","first-page":"eabj5413","DOI":"10.1126\/scitranslmed.abj5413","article-title":"Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern","volume":"13","author":"H Cho","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"7855","key":"pone.0274343.ref007","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Z Wang","year":"2021","journal-title":"Nature"},{"key":"pone.0274343.ref008","first-page":"1941","article-title":"Geneva 1211, Switzerland henaorestrepoa@who.int","volume":"399","author":"World Health Organization","year":"2022","journal-title":"Lancet 2022"},{"issue":"19","key":"pone.0274343.ref009","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"JH Beigel","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"pone.0274343.ref010","first-page":"693","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"RC Group","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"pone.0274343.ref011","doi-asserted-by":"crossref","first-page":"100549","DOI":"10.1016\/j.xcrm.2022.100549","article-title":"Antiviral agents for the treatment of COVID-19: Progress and challenges","volume":"3","author":"M Singh","year":"2022","journal-title":"Cell Reports Medicine"},{"issue":"13","key":"pone.0274343.ref012","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1080\/07391102.2020.1778535","article-title":"Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19","volume":"39","author":"C Selvaraj","year":"2021","journal-title":"Journal of Biomolecular Structure and Dynamics"},{"issue":"8","key":"pone.0274343.ref013","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211238","article-title":"Biochemical composition, transmission and diagnosis of SARS-CoV-2","volume":"41","author":"R Ahirwar","year":"2021","journal-title":"Bioscience Reports"},{"issue":"1","key":"pone.0274343.ref014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12250-016-3726-4","article-title":"Molecular mechanisms of coronavirus RNA capping and methylation","volume":"31","author":"Y Chen","year":"2016","journal-title":"Virologica Sinica"},{"issue":"4","key":"pone.0274343.ref015","doi-asserted-by":"crossref","first-page":"e1000863","DOI":"10.1371\/journal.ppat.1000863","article-title":"In Vitro Reconstitution of SARS-Coronavirus mRNA Cap Methylation","volume":"6","author":"M Bouvet","year":"2010","journal-title":"PLOS Pathogens"},{"issue":"4","key":"pone.0274343.ref016","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/v13040538","article-title":"NSP16 2\u2032-O-MTase in Coronavirus Pathogenesis: Possible Prevention and Treatments Strategies","volume":"13","author":"L-J Chang","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"pone.0274343.ref017","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/24725552211008863","article-title":"A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex","volume":"26","author":"A Khalili Yazdi","year":"2021","journal-title":"SLAS DISCOVERY: Advancing the Science of Drug Discovery"},{"issue":"6","key":"pone.0274343.ref018","doi-asserted-by":"crossref","first-page":"e1450","DOI":"10.1002\/wrna.1450","article-title":"Regulation and function of CMTR1-dependent mRNA cap methylation","volume":"8","author":"F Inesta-Vaquera","year":"2017","journal-title":"WIREs RNA"},{"issue":"3","key":"pone.0274343.ref019","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/07391102.2020.1828172","article-title":"Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2\u2019-O-ribose methyltransferase of SARS-CoV-2 coronavirus","volume":"40","author":"Y Jiang","year":"2022","journal-title":"Journal of Biomolecular Structure and Dynamics"},{"issue":"3","key":"pone.0274343.ref020","doi-asserted-by":"crossref","first-page":"e00202","DOI":"10.1128\/mSphere.00202-20","article-title":"The mRNA Cap 2-O-Methyltransferase CMTR1 Regulates the Expression of Certain Interferon-Stimulated Genes","volume":"5","author":"GD Williams","year":"2020","journal-title":"mSphere"},{"issue":"3","key":"pone.0274343.ref021","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/epi.15.113","article-title":"Methyltransferase-Glo: a universal, bioluminescent and homogenous assay for monitoring all classes of methyltransferases","volume":"8","author":"K Hsiao","year":"2016","journal-title":"Epigenomics"},{"key":"pone.0274343.ref022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.antiviral.2017.06.021","article-title":"Toward the identification of viral cap-methyltransferase inhibitors by fluorescence screening assay","volume":"144","author":"W Aouadi","year":"2017","journal-title":"Antiviral Research"},{"issue":"5","key":"pone.0274343.ref023","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/acscentsci.0c00501","article-title":"Assay Techniques and Test Development for COVID-19 Diagnosis","volume":"6","author":"LJ Carter","year":"2020","journal-title":"ACS Central Science"},{"issue":"6","key":"pone.0274343.ref024","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/24725552211000652","article-title":"Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry","volume":"26","author":"L-A Pearson","year":"2021","journal-title":"SLAS DISCOVERY: Advancing the Science of Drug Discovery"},{"issue":"30","key":"pone.0274343.ref025","doi-asserted-by":"crossref","first-page":"e2024302118","DOI":"10.1073\/pnas.2024302118","article-title":"Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay","volume":"118","author":"WD Jang","year":"2021","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"pone.0274343.ref026","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3390\/v13091722","article-title":"Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase","volume":"13","author":"E Benoni","year":"2021","journal-title":"Viruses"},{"issue":"37","key":"pone.0274343.ref027","doi-asserted-by":"crossref","first-page":"25783","DOI":"10.1074\/jbc.M114.577353","article-title":"Coronavirus Nsp10, a Critical Co-factor for Activation of Multiple Replicative Enzymes*","volume":"289","author":"M Bouvet","year":"2014","journal-title":"Journal of Biological Chemistry"},{"issue":"30","key":"pone.0274343.ref028","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1073\/pnas.1508686112","article-title":"Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex","volume":"112","author":"Y Ma","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"pone.0274343.ref029","doi-asserted-by":"crossref","first-page":"e1002294","DOI":"10.1371\/journal.ppat.1002294","article-title":"Biochemical and Structural Insights into the Mechanisms of SARS Coronavirus RNA Ribose 2\u2032-O-Methylation by nsp16\/nsp10 Protein Complex","volume":"7","author":"Y Chen","year":"2011","journal-title":"PLOS Pathogens"},{"issue":"2","key":"pone.0274343.ref030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.virusres.2012.05.017","article-title":"Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2\u2032-O-methyltransferase activity of nsp10\/nsp16 complex","volume":"167","author":"M Ke","year":"2012","journal-title":"Virus Research"},{"issue":"19","key":"pone.0274343.ref031","doi-asserted-by":"crossref","first-page":"14887","DOI":"10.1021\/acs.jmedchem.1c01440","article-title":"Synthetic Neutralizing Peptides Inhibit the Host Cell Binding of Spike Protein and Block Infection of SARS-CoV-2","volume":"64","author":"T Wang","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"16","key":"pone.0274343.ref032","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1128\/JVI.00948-15","article-title":"Coronavirus nsp10\/nsp16 Methyltransferase Can Be Targeted by nsp10-Derived Peptide In Vitro and In Vivo To Reduce Replication and Pathogenesis","volume":"89","author":"Y Wang","year":"2015","journal-title":"Journal of Virology"},{"issue":"1","key":"pone.0274343.ref033","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1021\/acs.jnatprod.0c00968","article-title":"Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2","volume":"84","author":"MP Christy","year":"2021","journal-title":"Journal of Natural Products"},{"issue":"1","key":"pone.0274343.ref034","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41467-020-17495-9","article-title":"Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin","volume":"11","author":"P Krafcikova","year":"2020","journal-title":"Nature Communications"},{"issue":"3","key":"pone.0274343.ref035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases","volume":"6","author":"C Liu","year":"2020","journal-title":"ACS Central Science"},{"key":"pone.0274343.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijbiomac.2020.05.184","article-title":"High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment","volume":"160","author":"B Naik","year":"2020","journal-title":"International Journal of Biological Macromolecules"},{"key":"pone.0274343.ref037","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/acsinfecdis.1c00131","article-title":"The structure-based design of SARS-CoV-2 nsp14 methyltransferase ligands yields nanomolar inhibitors","volume":"7","author":"T Otava","year":"2021","journal-title":"ACS Infect. Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T14:00:01Z","timestamp":1669730401000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274343"}},"subtitle":[],"editor":[{"given":"Chandrabose","family":"Selvaraj","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0274343","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.09.12.505486","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}